The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01981473?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
